Article
Multidisciplinary Sciences
Kota Morishita, Sakiko Soutome, Mitsunobu Otsuru, Saki Hayashida, Maho Murata, Miho Sasaki, Yukinori Takagi, Misa Sumi, Masahiro Umeda
Summary: The study found that a drug holiday of 3 months for medication-related osteonecrosis of the jaw in osteoporosis patients receiving antiresorptive agents does not promote sequestra separation or improve treatment outcomes, and early surgical therapy is recommended.
SCIENTIFIC REPORTS
(2022)
Article
Orthopedics
Wang-yong Zhu, Wei-fa Yang, Leilei Wang, Xinmiao Lan, Zhuo-ying Tao, Jiaxin Guo, Jiankun Xu, Ling Qin, Yu-xiong Su
Summary: This animal study found that an 8-week drug holiday prior to dental extractions can partially recover osteoclastic activity in osteoporosis rats, but does not alleviate the development of MRONJ-like lesion or exacerbate the osteoporotic condition in the femur. Longer-term drug holiday, or combination of drug holiday and other prophylaxes, could be explored in future studies for prevention of MRONJ in patients with osteoporosis.
JOURNAL OF ORTHOPAEDIC TRANSLATION
(2023)
Article
Endocrinology & Metabolism
Guang Yang, Roy Williams, Lishu Wang, Nosha Farhadfar, Yiqing Chen, Alexander T. Loiacono, Jiang Bian, Lexie Shannon Holliday, Joseph Katz, Yan Gong
Summary: This study evaluated the incidence and risk factors for medication-related osteonecrosis of the jaw (MRONJ) related to bisphosphonates (BPs) or denosumab in cancer patients. The results showed that the rates of MRONJ associated with BPs and denosumab were similar, but patients receiving sequential treatment of these two drug classes had a much higher risk of MRONJ.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Ilaria Roato, Rodolfo Mauceri, Vincenzo Notaro, Tullio Genova, Vittorio Fusco, Federico Mussano
Summary: The pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) involves various factors, and antiresorptive drugs (ARDs), such as bisphosphonates (BPs) and denosumab (Dmab), play a significant role in its development. The time exposure, cumulative dose, and administration intensity of these drugs are crucial in the treatment of patients, particularly cancer patients who have the highest incidence of MRONJ. BPs and Dmab have different mechanisms of action on bone and immune subsets, which ultimately contribute to the onset of MRONJ. However, there is a lack of data on the effects of Dmab, highlighting the need for further studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Nutrition & Dietetics
Luca Dalle Carbonare, Monica Mottes, Maria Teresa Valenti
Summary: Osteonecrosis of the jaw is a severe clinical condition characterized by exposed bone that does not heal over time. Diagnosis is primarily clinical with imaging feedback playing a confirmatory role. Medication-related osteonecrosis of the jaw, particularly induced by bisphosphonates, has been widely discussed, but the exact mechanism remains debatable.
Review
Medicine, General & Internal
Alejandro Lorenzo-Pouso, Jose Bagan, Leticia Bagan, Pilar Gandara-Vila, Cintia M. Chamorro-Petronacci, Pablo Castelo-Baz, Andres Blanco-Carrion, Maria Angeles Blanco-Fernandez, Oscar Alvarez-Calderon, Javier Carballo, Mario Perez-Sayans
Summary: This manuscript critically reviewed the medication-related osteonecrosis of the jaw (MRONJ), updating key terminology, concepts, and current trends in prevention and diagnosis, while examining therapeutic options available. By perusing relevant literature, the review updated the understanding of MRONJ, highlighting gaps in knowledge and emphasizing the need for further research.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Cell Biology
Camille Gaudet, Stephane Odet, Christophe Meyer, Brice Chatelain, Elise Weber, Anne-Laure Parmentier, Stephane Derruau, Sebastien Laurence, Cedric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Mathilde Fenelon, Jean-Christophe Fricain, Narcisse Zwetyenga, David Hoarau, Remi Curien, Eric Gerard, Aurelien Louvrier, Florelle Gindraux
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a complication caused by anti-resorptive agents and anti-angiogenesis drugs. We reviewed the literature and designed a questionnaire to collect information on clinical practices. However, we found missing data and a lack of consensus.
Review
Endocrinology & Metabolism
L. dos Santos Ferreira, L. G. Abreu, C. B. Calderipe, M. D. Martins, L. F. Schuch, A. C. U. Vasconcelos
Summary: The study aimed to integrate data on the use of TPTD for MRONJ cases, finding that TPTD in combination with another therapy, especially antibiotic therapy, can be considered an effective protocol for MRONJ.
OSTEOPOROSIS INTERNATIONAL
(2021)
Review
Toxicology
Bhumrapee Srivichit, Chanisa Thonusin, Nipon Chattipakorn, Siriporn C. Chattipakorn
Summary: Bisphosphonates are commonly used in the treatment of bone and joint diseases, but long-term use can lead to osteonecrosis. Osteonecrosis is characterized by cell death and impaired cell functions, with medication-related osteonecrosis of the jaw being the most concerning condition. In addition to surgical treatment, non-surgical interventions have been explored to mitigate bisphosphonate-induced osteonecrosis.
ARCHIVES OF TOXICOLOGY
(2022)
Review
Dentistry, Oral Surgery & Medicine
Islam E. Ali, Yuka Sumita
Summary: Medication-related osteonecrosis of the jaw (MRONJ) can be triggered by certain medications used to treat osteoporosis and bone cancer. Surgical reconstruction may not always be possible, and prosthetic intervention may be necessary. Patients should be aware of the risk of MRONJ associated with denture trauma.
JAPANESE DENTAL SCIENCE REVIEW
(2022)
Review
Oncology
Akanksha Srivastava, Graciela M. Nogueras Gonzalez, Yimin Geng, Alexander M. Won, Maria E. Cabanillas, Aung Naing, Jeffrey N. Myers, Yisheng Li, Mark S. Chambers
Summary: This study investigated the prevalence of MRONJ in patients receiving two or more sequential ARDs compared to a single antiresorptive drug. The results showed an increased prevalence of MRONJ associated with sequential ARD therapy, such as pamidronate-zoledronate and bisphosphonate-denosumab, when compared to single ARD therapy.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Dentistry, Oral Surgery & Medicine
Alexander Wick, Philipp Bankosegger, Sven Otto, Bettina Hohlweg-Majert, Timm Steiner, Florian Probst, Oliver Ristow, Christoph Pautke
Summary: This study identified several risk factors significantly increasing the onset of MRONJ in patients treated with DNO, including chemotherapy/hormonal therapy, DNO dosage, breast cancer, corticosteroid intake, hypertension, diabetes mellitus, periodontal disease, apical ostitis, and denture use. Switching medications did not affect the development of MRONJ.
CLINICAL ORAL INVESTIGATIONS
(2022)
Article
Biotechnology & Applied Microbiology
Stephane Odet, Christophe Meyer, Camille Gaudet, Elise Weber, Julie Quenot, Stephane Derruau, Sebastien Laurence, Lisa Bompy, Marine Girodon, Brice Chatelain, Cedric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Narcisse Zwetyenga, Philippe Marchetti, Anne-Sophie Hatzfeld, David Toubeau, Fabienne Pouthier, Xavier Lafarge, Heinz Redl, Mathilde Fenelon, Jean-Christophe Fricain, Roberta Di Pietro, Charlotte Ledouble, Thomas Gualdi, Anne-Laure Parmentier, Aurelien Louvrier, Florelle Gindraux
Summary: The use of human amniotic membrane (hAM) can promote tissue regeneration and healing in patients with medication-related osteonecrosis of the jaw (MRONJ). By using cryopreserved hAM, MRONJ can be effectively treated, leading to improved quality of life for patients.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Oncology
Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida
Summary: This study found that patients treated with denosumab for bone metastasis have a higher risk of developing medication-related osteonecrosis of the jaw (MRONJ) compared to those treated with zoledronic acid, highlighting the need for close monitoring for patients on denosumab.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Chemistry, Multidisciplinary
Krzysztof Wrobel, Maciej Sikora, Maciej Checinski, Maria Jas, Dariusz Chlubek
Summary: MRONJ is a condition that is becoming more common in dental and maxillofacial practice, requiring comprehensive, accessible, and up-to-date data. Besides bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies can also increase the risk of the disease. Thorough physical examination, periodic correction of dental prostheses, and adequate preparation for oral procedures can prevent or minimize the risk of MRONJ.
APPLIED SCIENCES-BASEL
(2021)